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Abstract
Aberrant hypo-methylation of DNA is evident in a range of human diseases including cancer and diabetes. Development of
sensitive assays capable of detecting traces of un-methylated DNA within methylated samples can be useful in several
situations. Here we describe a new approach, fast-COLD-MS-PCR, which amplifies preferentially un-methylated DNA
sequences. By employing an appropriate denaturation temperature during PCR of bi-sulfite converted DNA, fast-COLD-MS-
PCR enriches un-methylated DNA and enables differential melting analysis or bisulfite sequencing. Using methylation on the
MGMT gene promoter as a model, it is shown that serial dilutions of controlled methylation samples lead to the reliable
sequencing of un-methylated sequences down to 0.05% un-methylated-to-methylated DNA. Screening of clinical glioma
tumor and infant blood samples demonstrated that the degree of enrichment of un-methylated over methylated DNA can
be modulated by the choice of denaturation temperature, providing a convenient method for analysis of partially
methylated DNA or for revealing and sequencing traces of un-methylated DNA. Fast-COLD-MS-PCR can be useful for the
detection of loss of methylation/imprinting in cancer, diabetes or diet-related methylation changes.
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Introduction
The role of DNA promoter methylation in cancer genetics has
been widely studied and some of its mechanisms elucidated,
however, the implication of DNA hypomethylation in oncogenesis
is less well understood. Studies show a decrease in 5-methylcyt-
osine levels in cancer tissues compared to their surrounding
normal tissue in colon adenocarcinomas, Wilms’ tumors and
ovarian epithelial carcinomas, among others. The relationship of
DNA hypomethylation to tumorigenesis is important to consider
in view of cancer therapies that operate by decreasing DNA
methylation. [1]. Furthermore, during gonad development gene
imprinting takes place through parent of origin allele-specific
methylation processes. The loss of imprinting (i.e. un-methylation
of a previously methylated allele) may result in placental defects as
well as in a series of genetic conditions that could increase the risk
of cancer [2,3]. Loss of methylation is also important in diabetes,
where differential methylation occurs in genes that encode pre-
proinsulin where b-cells are mainly un-methylated compared to
other cell types. Detection of un-methylated pre-proinsulin DNA
in serum has been associated to pancreatic b-cell death. Thus
detecting DNA un-methylation at early stages of disease progres-
sion may provide actionable interventions in pre-diabetic stages
[4]. Given such possibilities, the identification of small traces of un-
methylated DNA within methylated DNA is of significance and is
clinically desirable in cancer, diabetes and in other fields where
epigenetics provides a potential link between lifestyle (diet, alcohol,
smoking) with diabetes, obesity and cancer [5,6].
A range of methods currently exist for detecting methylated or
un-methylated DNA including methylation-specific PCR [7–10],
differential enzymatic restriction methods [11], isothermal ampli-
fication methods [12], high resolution melting [13] or bisulfite
sequencing [14] carried out as traditional Sanger sequencing or
using next generation sequencing technologies. By revealing the
status of individual CpG di-nucleotides, sequencing provides the
most complete information on the methylation status of a target
region. On the other hand real-time methylation-specific PCR is
able to detect the presence of rare un-methylated alleles among an
excess of methylated alleles or vice versa, something which is
difficult to achieve with bisulfite sequencing alone. Below we
demonstrate that Co-amplification at Lower Denaturation tem-
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detection and sequencing of traces of un-methylated alleles within
a population of methylated alleles. This approach relies on the
substitution of the denaturation temperature (typically 95–98uC)
by a decreased denaturation temperature (critical denaturation
temperature, Tc). This allows the preferential amplification of
sequences that have a lower melting temperature. Detection can
be performed using an intercalating dye and melting analysis,
followed by direct sequencing of the resulting amplicons without
the need for specific reagents or use of special instrumentation.
We chose methylation of the gene encoding for O6
methylguanine methyl transferase (MGMT) as an example to
validate COLD Methylation-specific (MS)-PCR in DNA from
glioblastoma or infant blood samples. MGMT is of particular
importance in glioblastoma. It encodes an evolutionarily
conserved protein whose primary function is to repair guanine
nucleotides that are alkylated at the O6 position [18]. As O6-
methyl guanine constitutes the major cytotoxic lesion related to
temozolomide, the only efficacious chemotherapy against glio-
blastoma, MGMT serves as the primary determinant of
therapeutic response. MGMT promoter methylation leads to
decreased expression of MGMT, and this methylation pattern
have been associated with improved therapeutic response by
three independent, well-conducted clinical trials, including the
EORTIC-NCIC, NOA-8, and the Nordic trials [19]. As such,
methodologies for sensitive and reproducible detection MGMT
promoter methylation would better facilitate clinical management
of glioblastoma patients. Using COLD-MS-PCR we demonstrate
that we are able to amplify and sequence 0.05% of un-methylated
MGMT DNA within an excess of 99.95% of methylated MGMT
DNA.
Figure 1. Melting profiles of bisulfite-converted DNA from clinical samples following conventional PCR. Post-PCR melting profiles of
the 255 bp bisulfite-converted MGMT gene amplicon after conventional PCR. Examples of fully un-methylated DNA samples isolated from infant
blood (Panel A) and glioma samples (Panel B) are depicted. 100% methylated (M) and 100% un-methylated (U) DNA controls are used as reference
standards, demonstrating a ,5uC melting temperature difference among the two. Panel C. A glioma sample with mixed methylation/unmethylation
pattern is shown.
doi:10.1371/journal.pone.0094103.g001
Improved Detection of Un-Methylated DNA by COLD-PCR
PLOS ONE | www.plosone.org 2 April 2014 | Volume 9 | Issue 4 | e94103Materials and Methods
DNA, clinical samples and bisulfite treatment
Un-methylated and enzymatically methylated DNA (Millipore
Corporation, Billerica, MA, USA) were obtained and subjected to
bisulfite treatment using the EpiTect Bisulfite kit following
manufacturer’s recommendations (Qiagen Inc.). Additional Epi-
tect bisulfite-converted un-methylated and methylated controls
were obtained from Qiagen. Serial dilutions of un-methylated and
methylated DNA were prepared.
Two sets of clinical samples were tested, chosen for their
potential to harbor methylation (or lack of methylation) on the
MGMT gene. Glioma tumor tissue specimens (N=20), obtained
from the Division of Neurosurgery at the Beth Israel – Deaconess
Medical Center; and blood samples (N=10) isolated from blood of
infants at the Department of Pediatrics, Boston Medical Center.
Infant samples were obtained after written informed consent by
the mothers and following approval by the IRB committee of
Boston Medical Center. Glioma samples were also obtained
following written consent prior to surgery (BIDMC Division of
Neurosurgery) and following approval by the IRB committee of
DFCI/BIDMC. These samples were processed for DNA isolation
using the DNAeasy Blood & Tissue Kit (Qiagen) as described [20],
followed by bisulfite sequencing.
Methylation-specific fast-COLD-PCR (fast-COLD-MS-PCR)
Fast-COLD-PCR is the simplest version of COLD-PCR [15]. It
leads to the preferential amplification of sequences containing
genomic alterations that result to a reduction of the melting
temperature of the PCR amplicon and combines well with
downstream detection formats including high resolution melting
[21–24]. This property is exploited here for sensitive detection of
un-methylated DNA. During sodium bisulfite conversion of DNA,
deamination of un-methylated cytosines generates uracils whereas
5-methylcytosines remain unaffected. In a subsequent PCR
reaction uracil residues are amplified as thymines and 5-methyl-
cytosines as cytosines [14]. This results in a large difference in GC
content and melting temperature differential changes that can
then be exploited by COLD-PCR for selectively amplifying un-
methylated DNA.
PCR reactions, specific for bisulfite-converted DNA, were
designed and optimized to amplify a region of MGMT (O-6-
methyl-guanine-DNA methyltransferase) gene. A pre-amplifica-
tion of 379 bp using primers that bind target regions without CpG
sites 59-TTTGTTTTTTTTAGGTTTT-39 and 59-CCAAAA-
ACCCCAAACCCGA-39 with an annealing temperature of
48uC was performed as reported [25]. A second, nested PCR
reaction was designed using 59-GGATATGTTGGGATAGTT-39
[25] and 59-CACCTAAAAAACACTTAAAAC-39 with an an-
nealing temperature of 52uC to produce a 255 bp amplicon. The
second reaction was performed in a fast-COLD-PCR format to
favor the amplification of un-methylated DNA. Alternatively a
nested conventional PCR reaction was performed for comparison.
PCR reagents for both first and nested PCR reactions comprised
16 Colorless Gotaq reaction buffer, 2 mM MgCl2, 0.2 mmol/L
each dNTP, 0.25 mM each primer, 0.16 LCGreen+ dye (Idaho
Technologies Inc.), and 1 unit/ul GoTaq polymerase (Promega,
Madison, WI, USA). Fast-COLD-MS-PCR thermocycling proto-
Figure 2. Melting profiles of bisulfite-converted DNA from clinical samples following fast-COLD-MS-PCR. The effect of lowering the
denaturation temperature in PCR is depicted. Panel A. Glioma sample no. 3 was subjected to different critical denaturation temperature-Tc during
fast-COLD-MS-PCR. The modulation of the preferential amplification of the un-methylated DNA fraction is shown. Panel B. fast-COLD-MS-PCR
performed at a Tc of 84uC demonstrates that the amplification of the methylated DNA fraction is completely inhibited.
doi:10.1371/journal.pone.0094103.g002
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cycles of conventional PCR followed by 35 cycles at the selected
critical denaturation temperature (Tc) for 10 s, 52uC for 30 s and
72uC for 20 s with a final extension at 72uC). Conventional PCR
protocol was (initial denaturation at 95uC for 2 min, then 40 cycles
at 95uC for 30 s, 52uC for 30 s and 72uC for 20 s with a final
extension at 72uC for 5 min). Immediately following the extension
step of the nested reaction, PCR amplicons were subjected to
melting curve analysis on the Smartcycler II. Amplicons were
processed for Sanger sequencing. Experiments were repeated
three independent times.
Results and Discussion
Melting profiles of MGMT target gene regions using conven-
tional PCR-amplification of bisulfite-converted DNA from glioma
tumor samples and infant blood samples, along with fully un-
methylated and fully methylated DNA controls are depicted on
Figure 1, A-C. All the samples from infant blood generated
amplicons with melting profiles matching the 100% un-methylated
control DNA at the MGMT promoter region, and six represen-
tative samples are depicted on Figure 1A. The fully un-
methylated and fully methylated DNA produced amplicons with
melting temperatures (Tm) that differed by approximately 5uC
(Figure 1A). Out of 20 glioma samples tested, 19 samples
generated amplicons with melting profiles consistent with 100%
un-methylated control DNA. Figure 1B depicts two such un-
methylated glioma samples. A single glioma sample (no. 3)
generated a melting profile consistent with a mix of methylated
plus un-methylated DNA sequences at the MGMT promoter
region, which was different from the other glioma tumor samples
used to explain the reliability and stability of the approach
(Figure 1C).
Next we demonstrated that by modulating the denaturation
temperature during PCR, we can select with different efficiency
the un-methylated DNA fraction of a give sample. In Figure 2,
Panel A, we analyzed the effect of gradually lowering the
denaturation temperature during PCR, using for this purpose
glioma sample no. 3 with a mixture of un-methylated and
methylated DNA. By gradully shifting the Tc during PCR, a
gradual shifting of the un-methylated and methylated DNA
portions is observed. When a Tc of 84uC was used during fast-
COLD-MS-PCR, the methylated peak disappeared in the
Figure 3. Detection of un-methylated DNA within different abundances of methylated DNA background by conventional or fast-
COLD-MS-PCR. Panel A. Post-PCR melting profile of the 255 bp bisulfite-converted-specific amplicon after conventional PCR or COLD-PCR. Serial
dilutions of un-methylated (U) to methylated (M) genomic DNA are depicted (top half). Higher abundances of un-methylated DNA can be
discriminated from methylated DNA by the melt peak, whereas lower abundances are only detectable if fast-COLD-MS-PCR replaces conventional
PCR. Panel B. Sanger sequencing results of the 0.05% un-methylated (U): methylated (M) DNA sample as amplified by conventional and fast-COLD-
MS-PCR are shown (bottom half). Chromatograms are aligned and compared using SeqDoc, and the CpG methylation positions are revealed in the
middle panel.
doi:10.1371/journal.pone.0094103.g003
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amplification of un-methylated DNA (Figure 2B).
To examine the lowest fraction of un-methylated MGMT DNA
within an excess of methylated MGMT DNA that can be
preferentially amplified, detected and sequenced using fast-
COLD-MS-PCR we tested serial dilutions of un-methylated to
methylated DNA (Figure 3A). Using conventional MS-PCR,
fractions of un-methylated-to-methylated DNA of 20–80% gener-
ate the anticipated double peaks in their melting profiles.
However, in fractions below 5% the methylated peak cannot be
observed in either the melting profiles or the sequencing
chromatograms. In contrast, fast-COLD-MS-PCR can enrich
and detect the un-methylated DNA down to 0.05%. Furthermore,
direct sequencing of the product from an initial 0.05% un-
methylated DNA reveals un-methylated C at individual CpG
sequence positions Figure 3B.
Fast-COLD-MS-PCR utilizes primers that bind sequence
positions that do not contain CpG sites, i.e. they are neutral in
regards to CpG methylation. This is a potential advantage over
approaches that utilize methylation-specific primers, such as MS-
PCR or methyl-Light [7,8], as the methylation status of the primer
binding sites ideally should not pre-determine which fraction of the
target amplicons can be studied. Approaches like COBRA [11] or
methylation sensitive high resolution melting [13] employ CpG-
neutral primer binding sites and detect low levels of un-
methylation, but they do not enable bisulfite sequencing of the
product. The ability of fast-COLD-MS-PCR to modulate the
enrichment effect using graded denaturation temperatures pro-
vides a convenient method for analysis of partially methylated
DNA or for revealing and sequencing traces of un-methylated
DNA. Using fast-COLD-MS-PCR enabled the detection of traces
of un-methylated sequences by virtue of the Tm-lowering effect of
C.T transversions. On the other hand using different versions of
COLD-PCR (full-COLD-PCR [26]; ice-COLD-PCR [27]) it
should also be possible to reverse the process, i.e. enrich small
amounts of methylated DNA within an excess of un-methylated
DNA.
In summary, COLD-PCR technology can be adapted to reveal
traces of un-methylated DNA within a high excess of methylated
DNA.
When fast-COLD-MS-PCR was used to analyze bisulfite-
converted clinical samples and serially-diluted un-methylated
DNA in methylated DNA, low abundances of un-methylated
MGMT DNA, down to 0.05%, could be preferentially enriched
and sequenced. Thereby one can enrich and sequence traces of
un-methylated DNA which can precede disease progression in
cancer and diabetes, can be predictive of chemotherapy-caused
remission and are linked to diet and lifestyle-induced epigenetic
changes.
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